深交所举办“创享荟”活动 助力中国生物医药产业加速形成新质生产力

Group 1 - The event held by the Shenzhen Stock Exchange focused on the current status and future of innovative drugs, emphasizing the support of the capital market for high-quality development in the industry [1] - The theme "Gene Reconstruction, Evolution Towards New" reflects the acceleration of China's biopharmaceutical industry in forming new productive forces, transitioning from "generic drug combination" to "original innovation leadership" [1][2] - Participants discussed various aspects including regulatory policies, international cooperation, product differentiation, AI in drug development, financing valuation, and intellectual property protection [1][2] Group 2 - The biopharmaceutical industry is recognized as a strategic emerging industry crucial to national security and public welfare, with China transitioning from a "generic drug powerhouse" to an "innovative drug stronghold" [2][3] - The industry is experiencing a "golden period" of simultaneous quantity and quality improvement, driven by the synergy of policy, technology, and capital [2] - Companies are encouraged to explore international partnerships in innovative drug development and leverage capital markets to enhance global competitiveness [2][3] Group 3 - The biopharmaceutical sector has made significant strides in aligning with international standards, transitioning from a "follower" to a "leader" in innovation [3] - As market competition intensifies, innovative drug products must focus on quality and differentiated pipeline strategies, while managing risks related to intellectual property [3] - The industry is characterized by long R&D cycles and high upfront investments, necessitating further support from capital markets for rapid development [3][4] Group 4 - The Shenzhen Stock Exchange emphasizes the importance of capital markets in fostering innovation ecosystems and enhancing the efficiency of capital formation [4] - Recent initiatives include a comprehensive service chain for companies throughout their lifecycle, supporting the transformation of scientific research outcomes and facilitating connections between startups and investors [4] - The introduction of a new listing standard for the Growth Enterprise Market aims to support high-quality, unprofitable innovative companies in the biopharmaceutical and medical device sectors [4]